Caricamento...
The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and is known to interfere with the JAK / STAT signaling pathway, one of the critical cellular signaling pathways involved in the inflammatory response. This review presents an overview of SARS-CoV-2 and the COVID-19 pandemic, and then focuse...
Salvato in:
| Pubblicato in: | Cytokine Growth Factor Rev |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Elsevier Ltd.
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7305753/ https://ncbi.nlm.nih.gov/pubmed/32636055 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cytogfr.2020.06.013 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|